Stoke Therapeutics financials at a glance

+ Portfolio

The revenue of Stoke Therapeutics is reported as 0.00878 billion Dollars in the fiscal year 2023. The earnings were -2.38 Dollars per share in 2023, which was 8.46 higher than 2022. And about -0.08674 billion Dollars are reported as free cash flow in the financials of Stoke Therapeutics 2023. No dividends were paid to the shareholders of the Stoke Therapeutics stock NasdaqGS:STOK in the financial year 2023.

$8.78M

Revenue

$-2.38

Earnings Per Share

100.00%

Gross Margin %

$-,101.39M

Free Cash Flow

Revenue

8.78

Earnings Per Share

-2.38

Gross Margin %

100.00

Free Cash Flow

-,101.39

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018
Rev.	Revenue	N/A	$8.78M	$12.41M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-2.43	$-2.38	$-2.60	$-2.34	$-1.56	$-1.80	$-1.77
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	-0.00%	-0.00%	-0.00%	-0.00%	-0.00%	0
Sha.	Shares	N/AM	46.3M	44.15M	37.36M	36.66M	32.94M	0.73M
OCF	Operating Cash Flow	N/A	$-85.10M	$-31.87M	$-66.91M	$-42.22M	$-31.06M	$0.00M
FCF	Free Cash Flow	N/A	$-,101.39M	$-35.83M	$-68.11M	$-43.27M	$-32.69M	$0.00M
FCFS	Free Cash Flow Per Share	$-1.99	$-1.88	$-0.92	$-1.85	$-1.29	$-1.82	$-16.77

Stoke Therapeutics financials at a glance

Financials

Discover